U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H9Cl3N2OS
Molecular Weight 359.658
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRICLABENDAZOLE

SMILES

CSC1=NC2=CC(Cl)=C(OC3=C(Cl)C(Cl)=CC=C3)C=C2N1

InChI

InChIKey=NQPDXQQQCQDHHW-UHFFFAOYSA-N
InChI=1S/C14H9Cl3N2OS/c1-21-14-18-9-5-8(16)12(6-10(9)19-14)20-11-4-2-3-7(15)13(11)17/h2-6H,1H3,(H,18,19)

HIDE SMILES / InChI
Molecular Formula C14H9Cl3N2OS
Molecular Weight 359.658
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.drugs.com/international/triclabendazole.html | https://www.drugs.com/mmx/triclabendazole.html | https://www.ncbi.nlm.nih.gov/pubmed/15259481 | https://www.ncbi.nlm.nih.gov/pubmed/26312936

Triclabendazole, (brand name Avomec, Egaten, etc) is a member of the benzimidazole family of anthelmintics used to treat liver flukes, specifically fascioliasis and paragonimiasis. Triclabendazole used routinely since 1983 in veterinary practice for the treatment of fascioliasis. It was not used in humans until the 1989 epidemic of fascioliasis near the Caspian Sea when Iranian authorities approved the use of the veterinary formulation to treat the infection. Fasciolicidal not only against the adult worms present in the biliary ducts, but also against the immature larval stages of Fasciola migrating through the hepatic parenchyma. Triclabendazole is shown to penetrate into liver flukes by transtegumentary absorption followed by inhibition of the parasite's motility, probably related to the destruction of the microtubular structure, resulting in the death of the parasite; the immobilizing effect is paralleled by changes in the parasite's resting tegumental membrane potential, strongly inhibiting the release of proteolytic enzymes, a process that appears critical to the survival of the parasite. Side effects are generally few, but can include abdominal pain and headaches. Biliary colic may occur due to dying worms. While no harms have been found with use during pregnancy, triclabendazole has not been well studied in this population. Triclabendazole is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. It is not commercially available in the United States.

Originator

Approval Year

2019
339
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8228
 15.0 µM [IC50]
Inhibitor
8228
Inhibitor
8228
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8360
Egaten

Approved Use

Unknown
Curative
Approved
8360
Egaten

Approved Use

Unknown
Curative
Approved
8360
Egaten

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.34 μM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9663817/
10 mg/kg 1 times / day multiple, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TRICLABENDAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.16 μM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9663817/
10 mg/kg 1 times / day multiple, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TRICLABENDAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
1.16 μM
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
10 mg/kg single, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRICLABENDAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1.55 μM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9663817/
10 mg/kg 1 times / day multiple, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TRICLABENDAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5.72 μM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9663817/
10 mg/kg 1 times / day multiple, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TRICLABENDAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
5.72 μM × h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
10 mg/kg single, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRICLABENDAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
10 mg/kg single, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRICLABENDAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
3.3%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
10 mg/kg single, oral
dose: 10 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
TRICLABENDAZOLE plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
10 mg/kg 1 times / 8 hours multiple, oral (typical)
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
unhealthy, 12-60 years
n = 47
Health Status: unhealthy
Condition: Paragonimiasis
Age Group: 12-60 years
Sex: M+F
Population Size: 47
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
Other AEs: Abdominal pain, Headache...
Other AEs:
Abdominal pain (6.4%)
Headache (10.6%)
Dizziness (4.3%)
Jaundice (2.1%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
10 mg/kg 1 times / 8 hours multiple, oral (typical)
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
unhealthy, 4-68 years
n = 154
Health Status: unhealthy
Condition: Paragonimiasis
Age Group: 4-68 years
Sex: M+F
Population Size: 154
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
Other AEs: Dizziness, Abdominal pain...
Other AEs:
Dizziness (5.4%)
Abdominal pain (1.3%)
Diarrhea (1.3%)
Fever (1.9%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
10 mg/kg 1 times / 8 hours multiple, oral (typical)
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
unhealthy, 5-54 years
n = 35
Health Status: unhealthy
Condition: Paragonimiasis
Age Group: 5-54 years
Sex: M+F
Population Size: 35
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
Other AEs: Headache, Abdominal pain...
Other AEs:
Headache (5.7%)
Abdominal pain (5.7%)
Vomiting (2.9%)
Diarrhea (2.9%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
10 mg/kg 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11421375/
unhealthy, adult | children
n = 82
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 82
Sources:
https://pubmed.ncbi.nlm.nih.gov/11421375/
Other AEs: Abdominal pain, Biliary colic...
Other AEs:
Abdominal pain (grade 3, 1.2%)
Biliary colic (grade 1-2, 49%)
Jaundice (grade 1-2, 7.2%)
Epigastric pain (grade 1-2, 42.7%)
Nausea (grade 1-2, 8.5%)
Fever (grade 1-2, 8.5%)
Pruritus (grade 1-2, 6.1%)
Urticaria (grade 1-2, 2.4%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/11421375/
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 28
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 28
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Other AEs: Abdominal pain, Hyperhidrosis...
Other AEs:
Abdominal pain (93%)
Hyperhidrosis (25%)
Nausea (18%)
Urticaria (11%)
Vomiting (7%)
Headache (14%)
Pruritus (4%)
Musculoskeletal chest pain (4%)
Decreased appetite (18%)
Diarrhea (7%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
15 mg/kg single, oral (mean)
Recommended
Dose: 15 mg/kg
Route: oral
Route: single
Dose: 15 mg/kg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 214
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 214
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Other AEs: Bilirubin increased, AST increased...
Other AEs:
Bilirubin increased (6.8%)
AST increased (4.5%)
Alkaline phosphatase increased (4.2%)
ALT increased (3%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Other AEs: Abdominal pain, Hyperhidrosis...
Other AEs:
Abdominal pain (56%)
Hyperhidrosis (23%)
Vertigo (9%)
Nausea (8%)
Urticaria (7%)
Vomiting (6%)
Headache (6%)
Dyspnea (5%)
Pruritus (4%)
Asthenia (4%)
Musculoskeletal chest pain (4%)
Cough (4%)
Decreased appetite (3%)
Chest pain (3%)
Pyrexia (2%)
Jaundice (2%)
Chest discomfort (2%)
Constipation (< 2%)
Biliary colic (< 2%)
Arthralgia (< 2%)
Back pain (< 2%)
Spinal pain (< 2%)
Chromaturia (< 2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
10 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
unhealthy, mean age 16.3 years
n = 4
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age 16.3 years
Sex: M+F
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
Other AEs: Abdominal pain, Fatigue...
Other AEs:
Abdominal pain (grade 1, 100%)
Fatigue (grade 1, 50%)
Headache (grade 1-2, 75%)
Diarrhea (grade 1, 25%)
Nausea (grade 1, 75%)
Vomiting (grade 1, 25%)
Fever (grade 1-2, 25%)
Dizziness (grade 1, 50%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
unhealthy, mean age14.4 years
n = 16
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age14.4 years
Sex: M+F
Population Size: 16
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
Other AEs: Abdominal pain, Fatigue...
Other AEs:
Abdominal pain (grade 1-2)
Fatigue (grade 1)
Headache (grade 1-2)
Diarrhea (grade 1-2)
Vomiting (grade 1)
Fever (grade 1-2)
Dizziness (grade 1)
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
AEs

AEs

AESignificanceDosePopulation
Headache 10.6%
10 mg/kg 1 times / 8 hours multiple, oral (typical)
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
unhealthy, 12-60 years
n = 47
Health Status: unhealthy
Condition: Paragonimiasis
Age Group: 12-60 years
Sex: M+F
Population Size: 47
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
Jaundice 2.1%
10 mg/kg 1 times / 8 hours multiple, oral (typical)
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
unhealthy, 12-60 years
n = 47
Health Status: unhealthy
Condition: Paragonimiasis
Age Group: 12-60 years
Sex: M+F
Population Size: 47
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
Dizziness 4.3%
10 mg/kg 1 times / 8 hours multiple, oral (typical)
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
unhealthy, 12-60 years
n = 47
Health Status: unhealthy
Condition: Paragonimiasis
Age Group: 12-60 years
Sex: M+F
Population Size: 47
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
Abdominal pain 6.4%
10 mg/kg 1 times / 8 hours multiple, oral (typical)
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
unhealthy, 12-60 years
n = 47
Health Status: unhealthy
Condition: Paragonimiasis
Age Group: 12-60 years
Sex: M+F
Population Size: 47
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
Abdominal pain 1.3%
10 mg/kg 1 times / 8 hours multiple, oral (typical)
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
unhealthy, 4-68 years
n = 154
Health Status: unhealthy
Condition: Paragonimiasis
Age Group: 4-68 years
Sex: M+F
Population Size: 154
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
Diarrhea 1.3%
10 mg/kg 1 times / 8 hours multiple, oral (typical)
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
unhealthy, 4-68 years
n = 154
Health Status: unhealthy
Condition: Paragonimiasis
Age Group: 4-68 years
Sex: M+F
Population Size: 154
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
Fever 1.9%
10 mg/kg 1 times / 8 hours multiple, oral (typical)
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
unhealthy, 4-68 years
n = 154
Health Status: unhealthy
Condition: Paragonimiasis
Age Group: 4-68 years
Sex: M+F
Population Size: 154
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
Dizziness 5.4%
10 mg/kg 1 times / 8 hours multiple, oral (typical)
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
unhealthy, 4-68 years
n = 154
Health Status: unhealthy
Condition: Paragonimiasis
Age Group: 4-68 years
Sex: M+F
Population Size: 154
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
Diarrhea 2.9%
10 mg/kg 1 times / 8 hours multiple, oral (typical)
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
unhealthy, 5-54 years
n = 35
Health Status: unhealthy
Condition: Paragonimiasis
Age Group: 5-54 years
Sex: M+F
Population Size: 35
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
Vomiting 2.9%
10 mg/kg 1 times / 8 hours multiple, oral (typical)
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
unhealthy, 5-54 years
n = 35
Health Status: unhealthy
Condition: Paragonimiasis
Age Group: 5-54 years
Sex: M+F
Population Size: 35
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
Abdominal pain 5.7%
10 mg/kg 1 times / 8 hours multiple, oral (typical)
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
unhealthy, 5-54 years
n = 35
Health Status: unhealthy
Condition: Paragonimiasis
Age Group: 5-54 years
Sex: M+F
Population Size: 35
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
Headache 5.7%
10 mg/kg 1 times / 8 hours multiple, oral (typical)
Dose: 10 mg/kg, 1 times / 8 hours
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / 8 hours
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
unhealthy, 5-54 years
n = 35
Health Status: unhealthy
Condition: Paragonimiasis
Age Group: 5-54 years
Sex: M+F
Population Size: 35
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf
Urticaria grade 1-2, 2.4%
10 mg/kg 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11421375/
unhealthy, adult | children
n = 82
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 82
Sources:
https://pubmed.ncbi.nlm.nih.gov/11421375/
Epigastric pain grade 1-2, 42.7%
10 mg/kg 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11421375/
unhealthy, adult | children
n = 82
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 82
Sources:
https://pubmed.ncbi.nlm.nih.gov/11421375/
Biliary colic grade 1-2, 49%
10 mg/kg 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11421375/
unhealthy, adult | children
n = 82
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 82
Sources:
https://pubmed.ncbi.nlm.nih.gov/11421375/
Pruritus grade 1-2, 6.1%
10 mg/kg 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11421375/
unhealthy, adult | children
n = 82
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 82
Sources:
https://pubmed.ncbi.nlm.nih.gov/11421375/
Jaundice grade 1-2, 7.2%
10 mg/kg 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11421375/
unhealthy, adult | children
n = 82
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 82
Sources:
https://pubmed.ncbi.nlm.nih.gov/11421375/
Fever grade 1-2, 8.5%
10 mg/kg 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11421375/
unhealthy, adult | children
n = 82
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 82
Sources:
https://pubmed.ncbi.nlm.nih.gov/11421375/
Nausea grade 1-2, 8.5%
10 mg/kg 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11421375/
unhealthy, adult | children
n = 82
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 82
Sources:
https://pubmed.ncbi.nlm.nih.gov/11421375/
Abdominal pain grade 3, 1.2%
10 mg/kg 1 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11421375/
unhealthy, adult | children
n = 82
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 82
Sources:
https://pubmed.ncbi.nlm.nih.gov/11421375/
Urticaria 11%
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 28
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 28
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Headache 14%
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 28
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 28
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Decreased appetite 18%
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 28
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 28
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Nausea 18%
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 28
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 28
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Hyperhidrosis 25%
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 28
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 28
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Musculoskeletal chest pain 4%
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 28
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 28
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Pruritus 4%
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 28
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 28
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Diarrhea 7%
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 28
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 28
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Vomiting 7%
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 28
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 28
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Abdominal pain 93%
10 mg/kg 2 times / day multiple, oral
Recommended
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 28
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 28
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
ALT increased 3%
15 mg/kg single, oral (mean)
Recommended
Dose: 15 mg/kg
Route: oral
Route: single
Dose: 15 mg/kg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 214
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 214
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Alkaline phosphatase increased 4.2%
15 mg/kg single, oral (mean)
Recommended
Dose: 15 mg/kg
Route: oral
Route: single
Dose: 15 mg/kg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 214
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 214
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
AST increased 4.5%
15 mg/kg single, oral (mean)
Recommended
Dose: 15 mg/kg
Route: oral
Route: single
Dose: 15 mg/kg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 214
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 214
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Bilirubin increased 6.8%
15 mg/kg single, oral (mean)
Recommended
Dose: 15 mg/kg
Route: oral
Route: single
Dose: 15 mg/kg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 214
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 214
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Chest discomfort 2%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Jaundice 2%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Pyrexia 2%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Hyperhidrosis 23%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Chest pain 3%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Decreased appetite 3%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Asthenia 4%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Cough 4%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Musculoskeletal chest pain 4%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Pruritus 4%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Dyspnea 5%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Abdominal pain 56%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Headache 6%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Vomiting 6%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Urticaria 7%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Nausea 8%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Vertigo 9%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Arthralgia < 2%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Back pain < 2%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Biliary colic < 2%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Chromaturia < 2%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Constipation < 2%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Spinal pain < 2%
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
unhealthy, adult | children
n = 186
Health Status: unhealthy
Condition: fascioliasis
Age Group: adult | children
Sex: M+F
Population Size: 186
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf
Abdominal pain grade 1, 100%
10 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
unhealthy, mean age 16.3 years
n = 4
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age 16.3 years
Sex: M+F
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
Diarrhea grade 1, 25%
10 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
unhealthy, mean age 16.3 years
n = 4
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age 16.3 years
Sex: M+F
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
Vomiting grade 1, 25%
10 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
unhealthy, mean age 16.3 years
n = 4
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age 16.3 years
Sex: M+F
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
Dizziness grade 1, 50%
10 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
unhealthy, mean age 16.3 years
n = 4
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age 16.3 years
Sex: M+F
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
Fatigue grade 1, 50%
10 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
unhealthy, mean age 16.3 years
n = 4
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age 16.3 years
Sex: M+F
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
Nausea grade 1, 75%
10 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
unhealthy, mean age 16.3 years
n = 4
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age 16.3 years
Sex: M+F
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
Fever grade 1-2, 25%
10 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
unhealthy, mean age 16.3 years
n = 4
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age 16.3 years
Sex: M+F
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
Headache grade 1-2, 75%
10 mg/kg 1 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
unhealthy, mean age 16.3 years
n = 4
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age 16.3 years
Sex: M+F
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
Dizziness grade 1
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
unhealthy, mean age14.4 years
n = 16
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age14.4 years
Sex: M+F
Population Size: 16
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
Fatigue grade 1
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
unhealthy, mean age14.4 years
n = 16
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age14.4 years
Sex: M+F
Population Size: 16
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
Vomiting grade 1
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
unhealthy, mean age14.4 years
n = 16
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age14.4 years
Sex: M+F
Population Size: 16
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
Abdominal pain grade 1-2
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
unhealthy, mean age14.4 years
n = 16
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age14.4 years
Sex: M+F
Population Size: 16
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
Diarrhea grade 1-2
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
unhealthy, mean age14.4 years
n = 16
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age14.4 years
Sex: M+F
Population Size: 16
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
Fever grade 1-2
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
unhealthy, mean age14.4 years
n = 16
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age14.4 years
Sex: M+F
Population Size: 16
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
Headache grade 1-2
10 mg/kg 1 times / day single, oral
Dose: 10 mg/kg, 1 times / day
Route: oral
Route: single
Dose: 10 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
unhealthy, mean age14.4 years
n = 16
Health Status: unhealthy
Condition: fascioliasis
Age Group: mean age14.4 years
Sex: M+F
Population Size: 16
Sources:
https://pubmed.ncbi.nlm.nih.gov/21909440/
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1752

substrate
1010
inhibitor
1837

substrate
1193

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1509

CYP2B6
799

CYP2C8
901

CYP2C19
1463

CYP3A
211

CYP2E1
876

BCRP
691
CYP1A2
1032

CYP2C19
985

CYP3A
189

FMO
35

CYP1A1
348

CYP1B1
92

CYP2C18
139

UGT1A4
347

UGT1A8
283

UGT1A9
380

P-gp
1527
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2E1
964
 no
CYP2E1
964
 no
TCBZ-SO
1
CYP2E1
964
 no
TCBZ-SO2
1
CYP2D6
1875
 yes [Ki 0.009 uM]
CYP2B6
985
 yes [Ki 0.016 uM]
CYP2C8
955
 yes [Ki 0.018 uM]
CYP2D6
1875
 yes [Ki 0.05 uM]
TCBZ-SO
1
CYP2C9
1803
 yes [Ki 0.053 uM]
CYP2C19
1537
 yes [Ki 0.061 uM]
CYP1A2
1673
 yes [Ki 0.149 uM]
TCBZ-SO
1
CYP3A
295
 yes [Ki 0.166 uM]
CYP2C9
1803
 yes [Ki 0.22 uM]
TCBZ-SO2
1
CYP2C8
955
 yes [Ki 0.37 uM]
TCBZ-SO2
1
CYP2C19
1537
 yes [Ki 0.57 uM]
TCBZ-SO
1
CYP2B6
985
 yes [Ki 0.75 uM]
TCBZ-SO
1
CYP2C8
955
 yes [Ki 1.03 uM]
TCBZ-SO
1
CYP2B6
985
 yes [Ki 1.27 uM]
TCBZ-SO2
1
CYP2C9
1803
 yes [Ki 1.81 uM]
TCBZ-SO
1
CYP1A2
1673
 yes [Ki 12.5 uM]
TCBZ-SO2
1
CYP2D6
1875
 yes [Ki 13 uM]
TCBZ-SO2
1
CYP3A
295
 yes [Ki 2.31 uM]
TCBZ-SO2
1
CYP2C19
1537
 yes [Ki 2.77 uM]
TCBZ-SO2
1
CYP3A
295
 yes [Ki 4.32 uM]
TCBZ-SO
1
BCRP
765
 yes
BCRP
765
 yes
TCBZ-SO
1
BCRP
765
 yes
TCBZ-SO2
1
CYP1A2
1673
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP1A1
348
 yes
CYP1A1
348
 yes
TCBZ-SO
1
CYP1A2
1032
 yes
CYP1A2
1032
 yes
TCBZ-SO
1
CYP1B1
92
 yes
CYP1B1
92
 yes
TCBZ-SO
1
CYP2C18
139
 yes
CYP2C19
985
 yes
CYP2C19
985
 yes
TCBZ-SO
1
CYP2C9
1010
 yes
CYP2D6
1193
 yes
CYP3A
189
 yes
FMO
35
 yes
FMO
35
 yes
TCBZ-SO
1
P-gp
1527
 yes
UGT1A4
347
 yes
UGT1A8
283
 yes
UGT1A9
380
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
NO19265
https://www.001chemical.com/chem/68786-66-3
3B Scientific (Wuhan) Corp
3B2-0397
http://www.3bsc.com/index/pro_info.php?id=19753
AA Blocks
AA006H2T
http://www.aablocks.com/goods/Goods/detail?id=AA006H2T
AEchem Scientific Corp., USA
AE1-012796
http://www.aechemsc.com/info_products/AE1-012796.php
AHH Chemical co.,ltd
API-1377
http://www.ahhchemical.com/product/API-1377.html
AK Scientific, Inc. (AKSCI)
I018
http://www.aksci.com/item_detail.php?cat=I018
Aaron Chemicals
AR006HUL
http://www.aaronchem.com/68786-66-3
AbMole Bioscience
M3086
http://www.abmole.com/products/triclabendazole.html
Achemo Scientific Limited
AC-14758
http://www.achemo.com/search/?Keyword= 68786-66-3
Achemtek
0104-023305
http://www.achemtek.com/68786-66-3
Acros Organics
AC461960010
https://www.fishersci.com/shop/products/triclabendazole-98-acros-organics-1/AC461960010
Acros Organics
AC461960050
https://www.fishersci.com/shop/products/triclabendazole-98-acros-organics/AC461960050
Alfa Chemistry
AP68786663
https://reagents.alfa-chemistry.com/product/triclabendazole-cas-68786-66-3-15149.html
Alfa Chemistry
68786-66-3
https://www.alfa-chemistry.com/triclabendazole-cas-68786-66-3-item-293302.htm
Ambinter
Amb1064227
http://www.ambinter.com/reference/1064227
Angene
AGN-PC-0WAFFY
http://www.angenechemical.com/productshow/AGN-PC-0WAFFY.html
Anward
ANW-42745
http://www.anward.com/pro_result/29972
ApexBio Technology
B1860
http://www.apexbt.com/triclabendazole-28619.html
Ark Pharm
AK-68238
http://www.arkpharminc.com/products/68786-66-3.html
Aurum Pharmatech LLC
MP-0274
http://www.Aurumpharmatech.com/Product/ProductDetails/MP_0274
BLD Pharm
BD34628
http://www.bldpharm.com/products/68786-66-3.html
BioCrick
BCC4742
http://www.biocrick.com/Triclabendazole-BCC4742.html
CSNpharm
CSN16451
https://www.csnpharm.com/products/triclabendazole.html
Chem Scene
CS-2859
http://www.chemscene.com/68786-66-3.html
ChemMol
30101568
http://www.chemmol.com/chemmol/30101568.html
ChemMol
49403233
http://www.chemmol.com/chemmol/49403233.html
ChemMol
99130410
http://www.chemmol.com/chemmol/99130410.html
ChemShuttle
151876
http://www.chemshuttle.com/catalogsearch/result/?q=68786-66-3&cat=
Chemspace
CSSB00016988883
https://chem-space.com/CSSB00016988883
Clearsynth
CS-W-00074
https://www.clearsynth.com/en/CSW00074.html
DC Chemicals
DC32992
http://www.dcchemicals.com//product_show-Triclabendazole.html
Finetech
FT-0602564
http://www.finetechnology-ind.com/prod/detail/pub/68786-66-3.html
Glentham Life Sciences
GP3360
http://www.glentham.com/products/product/GP3360/
Hairui
HR115473
http://www.hairuichem.com/en/product/68786-66-3.html
Huateng Pharma
F80017899
http://en.huatengsci.com/product/Triclabendazole.html
LGC Standards
DRE-A17795000AL-100
https://www.lgcstandards.com/US/en/p/DRE-A17795000AL-100
LGC Standards
DRE-C17795000
https://www.lgcstandards.com/US/en/p/DRE-C17795000
LGC Standards
LGCFOR0313.00
https://www.lgcstandards.com/US/en/p/LGCFOR0313.00
LGC Standards
MM0313.00
https://www.lgcstandards.com/US/en/p/MM0313.00
Lab Network
LN00176318
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00176318
Matrix Scientific
76003
https://www.matrixscientific.com/076003.html
MedChem Express
HY-B0621
https://www.medchemexpress.com/triclabendazole.html
Molcore
CS19265
https://www.molcore.com/product/68786-66-3
MuseChem
A000387
https://www.musechem.com/product/A000387.html
OChem
5477
http://www.ocheminc.com/index.php?act=psearch&pid=786T663
Oakwood
79305
http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=64479&ExtHyperLink=1
Parchem
34541
http://www.parchem.com/chemical-supplier-distributor/Triclabendazole-024541.aspx
Sigma-Aldrich
32802_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/32802?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
Y0001723_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/y0001723?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
Y0001737_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/y0001737?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule
S545823
http://www.smolecule.com/products/s545823
Synblock Inc
SB17173
http://www.synblock.com/product/68786-66-3.html
TCI (Tokyo Chemical Industry)
T2826
http://www.tcichemicals.com/eshop/en/us/commodity/T2826/index.html
THE BioTek
bt-286752
https://www.thebiotek.com/product/inhibitors/bt-286752
VladaChem
VL282319-10G
https://www.vladachem.com/product.php?products=68786-66-3
Yuhao Chemical
RT19019
http://www.chemyuhao.com/68786-66-3.html
abcr GmbH
AB425871
http://www.abcr.com/shop/en/AB425871
eNovation Chemicals
D520206
https://www.enovationchem.com/ProductDetails.asp?ProductID=D520206
iChemical
EBD22541
http://www.ichemical.com/products/68786-66-3.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
mcule
MCULE-8131756770
https://mcule.com/MCULE-8131756770/
PubMed

PubMed

TitleDatePubMed
Experimental infection of rabbits with Fasciola gigantica and treatment with triclabendazole (TCBZ) or BT6: parasitological, haematological and immunological findings.
2001
An ultrasensitive capture ELISA for detection of Fasciola hepatica coproantigens in sheep and cattle using a new monoclonal antibody (MM3).
2004 Aug
Liver, spleen, pancreas and kidney involvement by human fascioliasis: imaging findings.
2004 Aug 4
Response of two isolates of Fasciola hepatica to treatment with triclabendazole in vivo and in vitro.
2004 Dec
Randomized trial of a single, double and triple dose of 10 mg/kg of a human formulation of triclabendazole in patients with fascioliasis.
2004 Nov
[Human infection with Dicrocoelium dendriticum].
2004 Nov 19
Measurement of triclabendazole and its metabolites in liver flukes: method development and full validation.
2004 Sep 3
Monitoring and treatment of Fascioloides magna in semi-farm red deer husbandry in Croatia.
2005 Aug
Triclabendazole for the treatment of fascioliasis and paragonimiasis.
2005 Dec
Separation and characterization of synthetic impurities of triclabendazole by reversed-phase high-performance liquid chromatography/electrospray ionization mass spectrometry.
2005 Feb 7
[Four cases of hepatic fascioliasis mimicking cholangiocarcinoma].
2005 Jun
Lack of reversion in triclabendazole-resistant Fasciola hepatica.
2005 Mar 12
Eurytrema pancreaticum: the in vitro effect of praziquantel and triclabendazole on the adult fluke.
2005 Nov
Emerging foodborne trematodiasis.
2005 Oct
Altered drug influx/efflux and enhanced metabolic activity in triclabendazole-resistant liver flukes.
2005 Oct
[Design of a Russian sample of the antifascioliasis antihelminthic triclabendazole and evaluation of its therapeutic efficiency].
2005 Oct-Dec
Triclabendazole: new skills to unravel an old(ish) enigma.
2005 Sep
[Therapeutic alternatives in case of failure of first-line treatment of intestinal helminthiasis in adults].
2006 Aug
Triclabendazole and its two main metabolites lack activity against Schistosoma mansoni in the mouse model.
2006 Aug
Adult triclabendazole-resistant Fasciola hepatica: surface and subsurface tegumental responses to in vitro treatment with the sulphoxide metabolite of the experimental fasciolicide compound alpha.
2006 Aug
Stage-specific differences in fecundity over the life-cycle of two characterized isolates of the liver fluke, Fasciola hepatica.
2006 Aug
Resistance-induced changes in triclabendazole transport in Fasciola hepatica: ivermectin reversal effect.
2006 Dec
Treatment of fascioliasis in human infections.
2006 Feb
Field trial on comparative efficacy of four fasciolicides against natural liver fluke infection in cattle.
2006 Feb 18
Seasonal differences in the incidence of infection with Fasciola gigantica in Cambodian cattle.
2006 Jan
Eight cases of fascioliasis: clinical and microbiological features.
2006 Jan
Response from Savioli and colleagues from the Department of Neglected Tropical Diseases, World Health Organization.
2006 Jun
Assessment of the main metabolism pathways for the flukicidal compound triclabendazole in sheep.
2006 Jun
Fasciola hepatica infection: clinical and computerized tomographic findings of ten patients.
2006 Mar
Systemic vasculitis associated with Fasciola hepatica infection.
2006 Mar-Apr
[Hepatobiliary fasciolasis without eosinophilia].
2006 Oct
Fasciola hepatica: morphological effects of a combination of triclabendazole and clorsulon against mature fluke.
2006 Oct
Resistance of Fasciola hepatica to triclabendazole and albendazole in sheep in Spain.
2006 Sep 23
Understanding triclabendazole resistance.
2007 Apr
Fasciola hepatica: ultrastructural effects of a combination of triclabendazole and clorsulon against mature fluke.
2007 Apr
Human fascioliasis: a case of hyperinfection and an update for clinicians.
2007 Fall
The use of MM3 monoclonal antibodies for the early immunodiagnosis of ovine fascioliasis.
2007 Feb
A case of human fasciolosis: discrepancy between egg size and genotype of Fasciola sp.
2007 Feb
Immature triclabendazole-resistant Fasciola hepatica: tegumental responses to in vitro treatment with the sulphoxide metabolite of the experimental fasciolicide compound alpha.
2007 Jan
[New drugs against parasitic diseases].
2007 Jan 31
Controlling fasciolosis in the Bolivian Altiplano.
2007 Jun
Effect of Fascioliasis on the pharmacokinetic parameters of triclabendazole in human subjects.
2007 Jun
The effect of diet type on the plasma disposition of triclabendazole in goats.
2007 Jun
An in vitro effect of propolis on adult worms of Fasciola gigantica.
2007 Mar 31
Obstructive jaundice with fever and eosinophilia.
2007 Nov
[Fascioliasis: a 23-year retrospective study].
2007 Nov
Fasciola hepatica: the infectivity of cattle-origin miracidia had increased over the past years in central France.
2007 Sep
A field trial of production and financial consequences of helminthosis control in sheep production in Ethiopia.
2008 Apr 17
Natural history, clinicoradiologic correlates, and response to triclabendazole in acute massive fascioliasis.
2008 Feb
Use of triclabendazole for treatment of patients co-infected by Fasciola spp. and S. mansoni in Behera Governorate, Egypt.
2008 Mar
Patents

Patents

BE865870
1
DE2815621
1
NL7803886
1

Sample Use Guides

In Vivo Use Guide
10 mg per kg of body weight as a single dose
Route of Administration: Oral
In Vitro Use Guide
Triclabendazole was tested in vitro against recently excysted metacercariae. Triclabendazole was evaluated at concentrations of 10 and 50 mg/L., Triclabendazole demonstrated a fasciolicidal efficacy of 100% at a concentration of 10 and 50 mg/L at 24, 48 h and 72 hours post-treatment
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:50:42 UTC 2023
Edited
by admin
on Wed Jul 05 23:50:42 UTC 2023
Record UNII
4784C8E03O
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TRICLABENDAZOLE
INN   MART.   MI  
USAN   INN  
Official Name English
1H-BENZIMIDAZOLE, 6-CHLORO-5-(2,3-DICHLOROPHENOXY)-2-(METHYLTHIO)-
Systematic Name English
NVP-EGA230
Code English
Triclabendazole [WHO-DD]
Common Name English
TRICLABENDAZOLE [MART.]
Common Name English
TRICLABENDAZOLE [ORANGE BOOK]
Common Name English
EGATEN
Brand Name English
triclabendazole [INN]
Common Name English
EGA230B
Code English
TRICLABENDAZOLE [MI]
Common Name English
5-Chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole
Systematic Name English
FASINEX
Brand Name English
TRICLABENDAZOLE [USAN]
Common Name English
NSC-759250
Code English
Classification Tree Code System Code
WHO-VATC QP52AC01
Created by admin on Wed Jul 05 23:50:42 UTC 2023 , Edited by admin on Wed Jul 05 23:50:42 UTC 2023
WHO-ATC P02BX04
Created by admin on Wed Jul 05 23:50:42 UTC 2023 , Edited by admin on Wed Jul 05 23:50:42 UTC 2023
FDA ORPHAN DRUG 564216
Created by admin on Wed Jul 05 23:50:42 UTC 2023 , Edited by admin on Wed Jul 05 23:50:42 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 6.1.3
Created by admin on Wed Jul 05 23:50:42 UTC 2023 , Edited by admin on Wed Jul 05 23:50:42 UTC 2023
NCI_THESAURUS C250
Created by admin on Wed Jul 05 23:50:42 UTC 2023 , Edited by admin on Wed Jul 05 23:50:42 UTC 2023
FDA ORPHAN DRUG 525416
Created by admin on Wed Jul 05 23:50:42 UTC 2023 , Edited by admin on Wed Jul 05 23:50:42 UTC 2023
Code System Code Type Description
CAS
68786-66-3
Created by admin on Wed Jul 05 23:50:42 UTC 2023 , Edited by admin on Wed Jul 05 23:50:42 UTC 2023
PRIMARY
EVMPD
SUB11267MIG
Created by admin on Wed Jul 05 23:50:42 UTC 2023 , Edited by admin on Wed Jul 05 23:50:42 UTC 2023
PRIMARY
NCI_THESAURUS
C75236
Created by admin on Wed Jul 05 23:50:42 UTC 2023 , Edited by admin on Wed Jul 05 23:50:42 UTC 2023
PRIMARY
SMS_ID
100000092537
Created by admin on Wed Jul 05 23:50:42 UTC 2023 , Edited by admin on Wed Jul 05 23:50:42 UTC 2023
PRIMARY
MERCK INDEX
M11087
Created by admin on Wed Jul 05 23:50:42 UTC 2023 , Edited by admin on Wed Jul 05 23:50:42 UTC 2023
PRIMARY Merck Index
MESH
C039276
Created by admin on Wed Jul 05 23:50:42 UTC 2023 , Edited by admin on Wed Jul 05 23:50:42 UTC 2023
PRIMARY
DRUG CENTRAL
2734
Created by admin on Wed Jul 05 23:50:42 UTC 2023 , Edited by admin on Wed Jul 05 23:50:42 UTC 2023
PRIMARY
EPA CompTox
DTXSID7043952
Created by admin on Wed Jul 05 23:50:42 UTC 2023 , Edited by admin on Wed Jul 05 23:50:42 UTC 2023
PRIMARY
NSC
759250
Created by admin on Wed Jul 05 23:50:42 UTC 2023 , Edited by admin on Wed Jul 05 23:50:42 UTC 2023
PRIMARY
RXCUI
2118525
Created by admin on Wed Jul 05 23:50:42 UTC 2023 , Edited by admin on Wed Jul 05 23:50:42 UTC 2023
PRIMARY
LACTMED
Triclabendazole
Created by admin on Wed Jul 05 23:50:42 UTC 2023 , Edited by admin on Wed Jul 05 23:50:42 UTC 2023
PRIMARY
FDA UNII
4784C8E03O
Created by admin on Wed Jul 05 23:50:42 UTC 2023 , Edited by admin on Wed Jul 05 23:50:42 UTC 2023
PRIMARY
DRUG BANK
DB12245
Created by admin on Wed Jul 05 23:50:42 UTC 2023 , Edited by admin on Wed Jul 05 23:50:42 UTC 2023
PRIMARY
ChEMBL
CHEMBL1086440
Created by admin on Wed Jul 05 23:50:42 UTC 2023 , Edited by admin on Wed Jul 05 23:50:42 UTC 2023
PRIMARY
PUBCHEM
50248
Created by admin on Wed Jul 05 23:50:42 UTC 2023 , Edited by admin on Wed Jul 05 23:50:42 UTC 2023
PRIMARY
DAILYMED
4784C8E03O
Created by admin on Wed Jul 05 23:50:42 UTC 2023 , Edited by admin on Wed Jul 05 23:50:42 UTC 2023
PRIMARY
USAN
EF-110
Created by admin on Wed Jul 05 23:50:42 UTC 2023 , Edited by admin on Wed Jul 05 23:50:42 UTC 2023
PRIMARY
INN
5003
Created by admin on Wed Jul 05 23:50:42 UTC 2023 , Edited by admin on Wed Jul 05 23:50:42 UTC 2023
PRIMARY
RS_ITEM_NUM
1681611
Created by admin on Wed Jul 05 23:50:42 UTC 2023 , Edited by admin on Wed Jul 05 23:50:42 UTC 2023
PRIMARY
WIKIPEDIA
TRICLABENDAZOLE
Created by admin on Wed Jul 05 23:50:42 UTC 2023 , Edited by admin on Wed Jul 05 23:50:42 UTC 2023
PRIMARY
Related Record Type Details
CYTOCHROME P450 1A2
METABOLIC ENZYME -> SUBSTRATE
MAJOR
CYTOCHROME P450 2C19
METABOLIC ENZYME -> SUBSTRATE
FETAL HEPATIC FLAVIN-CONTAINING MONOOXYGENASE 1 (HUMAN)
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 2B6
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 2D6
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 1A2
METABOLIC ENZYME -> INHIBITOR
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 2C8
METABOLIC ENZYME -> SUBSTRATE
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
CYTOCHROME P450 2C9
METABOLIC ENZYME -> SUBSTRATE
FASCIOLA HEPATICA
TARGET ORGANISM->INHIBITOR
CYTOCHROME P450 2C19
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 2C9
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 2A6
METABOLIC ENZYME -> INHIBITOR
CYTOCHROME P450 2D6
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
FASCIOLA GIGANTICA
TARGET ORGANISM->INHIBITOR
CYTOCHROME P450 1A1
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 1B1
METABOLIC ENZYME -> SUBSTRATE
FETAL HEPATIC FLAVIN-CONTAINING MONOOXYGENASE 3 (HUMAN)
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
Structure of TRICLABENDAZOLE SULFONE
METABOLITE ACTIVE -> PARENT
MAJOR
PLASMA
Structure of TRICLABENDAZOLE SULFOXIDE
METABOLITE ACTIVE -> PARENT
MAJOR
PLASMA
Structure of 5-CHLORO-6-(2,3-DICHLOROPHENOXY)-1H-BENZIMIDAZOLE-2-THIOL
METABOLITE -> PARENT
Related Record Type Details
Structure of TRICLABENDAZOLE SULFOXIDE
IMPURITY -> PARENT
FOR VETERINARY USE
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 4-CHLORO-5-(2,3-DICHLOROPHENOXY)-2-NITROANILINE
IMPURITY -> PARENT
FOR VETERINARY USE
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 5-CHLORO-6-(2,3-DICHLOROPHENOXY)-1H-BENZIMIDAZOLE-2-THIOL
IMPURITY -> PARENT
FOR VETERINARY USE
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of TRICLABENDAZOLE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966